Compare · KROS vs NVO
KROS vs NVO
Side-by-side comparison of Keros Therapeutics Inc. (KROS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KROS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 940.9x KROS ($203.9M).
- Over the past year, KROS is down 28.6% and NVO is down 45.2% - KROS leads by 16.6 points.
- KROS has been more active in the news (10 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 22 for KROS).
- Company
- Keros Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $10.05-2.33%
- $41.34-3.73%
- Market cap
- $203.9M
- $191.82B
- 1M return
- -13.51%
- -9.69%
- 1Y return
- -28.65%
- -45.20%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 10
- 8
- Recent ratings
- 22
- 25
Keros Therapeutics Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest KROS
- Director Seth Alpna was granted 7,142 shares, increasing direct ownership by 136% to 12,392 units (SEC Form 4)
- Director Seth Alpna sold $28,140 worth of shares (2,625 units at $10.72) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 9,767 units (SEC Form 4)
- Director Gray Mary Ann was granted 7,142 shares, increasing direct ownership by 136% to 12,392 units (SEC Form 4)
- Director Farzan Nima was granted 7,142 shares, increasing direct ownership by 136% to 12,392 units (SEC Form 4)
- Director Bienaime Jean Jacques was granted 7,142 shares, increasing direct ownership by 76% to 16,592 units (SEC Form 4)
- Director Knowles Julius was granted 7,142 shares, increasing direct ownership by 111% to 13,583 units (SEC Form 4)
- Keros Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Keros Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
- Director Bienaime Jean Jacques bought $10,580 worth of shares (1,000 units at $10.58), increasing direct ownership by 12% to 9,450 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care